Jeremy Feldman, MD
Pulmonary Disease · Bend, ORNPI 1689681025
Payments from drug & device makers
Across 705 payments — averaging $2909.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$538K
- Medtronic$290K
- Actelion Pharmaceuticals, Ltd$267K
- United Therapeutics Corporation$265K
- Actelion Pharmaceuticals US, Inc.$175K
- Janssen Research & Development, LLC$170K
- plus $348K from 27 others
Across 1 payment — averaging $99.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$99
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 58 | $538,058 |
| Medtronic(2 entities) | 59 | $289,516 |
| Actelion Pharmaceuticals, Ltd | 63 | $266,748 |
| United Therapeutics Corporation | 196 | $264,531 |
| Actelion Pharmaceuticals US, Inc. | 165 | $174,643 |
| Janssen Research & Development, LLC | 59 | $169,514 |
| Acceleron Pharma, Inc. | 17 | $107,157 |
| Cumberland Pharmaceuticals, Inc. | 10 | $98,790 |
| Bayer | 18 | $77,158 |
| Enzyvant Therapeutics, Inc. | 3 | $22,824 |
| Novartis | 1 | $16,186 |
| Boehringer Ingelheim | 10 | $7,433 |
| Sumitomo Pharma America, Inc. | 13 | $7,260 |
| AstraZeneca | 2 | $5,952 |
| Gilead | 7 | $4,403 |
| Vertex | 1 | $500 |
| Inari Medical, Inc. | 1 | $296 |
| Insmed, Inc. | 3 | $63 |
| Amgen | 2 | $57 |
| Pulmonx Corporation | 2 | $38 |
| Sanofi | 2 | $31 |
| Pharmacosmos Therapeutics Inc. | 1 | $30 |
| GSK | 2 | $29 |
| Verona Pharma, Inc. | 1 | $28 |
| Olympus America Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Abbott | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Viiv Healthcare Company | 1 | $13 |
| Electromed, Inc. | 1 | $12 |
How this compares
$2,051,394 in reported general payments places this provider in the 95th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Bend
- Matthew HegewaldBend$159K
- Louis D'avignonBend$4K
- Kevin ShererBend$2K
- Thomas KelleyBend$2K
- Richard MularskiClackamas$2.4M
- Jeffrey RobinsonPortland$1.8M
- Aaron TrimblePortland$1M
- Stephen YauPortland$984K
- Alan BarkerPortland$540K
- David HotchkinPortland$521K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.